CoChat

PROTAC’ing oncoproteins: targeted protein degradation for cancer therapy

Open access
Kelm, Jeremy M., Pandey, Deepti S., Malin, Evan, Kansou, Hussein, Arora, Sahil, Kumar, Raj, Gavande, Navnath S. · 2023 · Molecular Cancer
Cited by 110

The DOI matches its Crossref record; 89 of the 89 references it cites were found in a registry or an index.

Abstract

Molecularly targeted cancer therapies substantially improve patient outcomes, although the durability of their effectiveness can be limited. Resistance to these therapies is often related to adaptive changes in the target oncoprotein which reduce binding affinity. The arsenal of targeted cancer therapies, moreover, lacks coverage of several notorious oncoproteins with challenging features for inhibitor development. Degraders are a relatively new therapeutic modality which deplete the target protein by hijacking the cellular protein destruction machinery. Degraders offer several advantages for cancer therapy including resiliency to acquired mutations in the target protein, enhanced selectivity, lower dosing requirements, and the potential to abrogate oncogenic transcription factors and scaffolding proteins. Herein, we review the development of proteolysis targeting chimeras (PROTACs) for selected cancer therapy targets and their reported biological activities. The medicinal chemistry of PROTAC design has been a challenging area of active research, but the recent advances in the field will usher in an era of rational degrader design.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s12943-022-01707-5

Cites

89 of 89 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 89 references

Cited by

See all 110

Metadata

Authors
Kelm, J. M., Pandey, D. S., Malin, E., Kansou, H., Arora, S., Kumar, R., & Gavande, N. S.
Venue
Molecular Cancer
Published
2023-03-30
Volume
22
Issue
1
Pages
62-62
ISSN
1476-4598 (ISSN-L)
OpenAlex
W4361277745
Cited by
110
References
89
FWCI
8.22
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: PROTAC’ing oncoproteins: targeted protein degradation for cancer therapy. https://app.cochat.ai/papers/10.1186/s12943-022-01707-5
The paper
Kelm, J. M., Pandey, D. S., Malin, E., Kansou, H., Arora, S., Kumar, R., & Gavande, N. S. (2023). PROTAC’ing oncoproteins: targeted protein degradation for cancer therapy. Molecular Cancer. https://doi.org/10.1186/s12943-022-01707-5

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.